Cortechs.ai Gains FDA Clearance for NeuroQuant PET
COVINGTON, Ky., August 18, 2026 Cortechs.ai announced that its NeuroQuant® PET platform has received FDA 510(k) clearance (K261916) for...
Cognitive Impairment
Advertisement
C2N Diagnostics Expands PrecivityAD2 Use in UK Alzheimer’s Diagnosis
ST. LOUIS, July 29, 2026 C2N Diagnostics, LLC announced that researchers in the United Kingdom are integrating its PrecivityAD2®...
Subtle Medical Gains FDA Clearance for SubtleHD PET
MENLO PARK, Calif., May 27, 2026 Subtle Medical, a leading developer of AI-powered medical imaging software, has announced that...
TOBY Gains FDA Breakthrough Status for Alzheimer’s Test
AUSTIN, Texas, May 26, 2026 TOBY, Inc., a biotechnology company focused on non-invasive disease detection technologies, has announced that...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
Advertisement
